The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I multicenter trial of CUDC-907 in children and young adults with relapsed/refractory solid tumors, CNS tumors, and lymphomas.
 
David Stephen Shulman
No Relationships to Disclose
 
Cecilia Carlowicz
No Relationships to Disclose
 
Clay Gustafson
No Relationships to Disclose
 
Kieuhoa Tran Vo
No Relationships to Disclose
 
Elizabeth Fox
Research Funding - Ignyta (Inst)
Travel, Accommodations, Expenses - Helsinn Therapeutics
Other Relationship - Helsinn Therapeutics
 
Jodi Ann Muscal
Research Funding - Bristol-Myers Squibb (Inst); Celldex (Inst); Curis (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Oncternal Therapeutics (Inst); Pfizer (Inst); Synergene (Inst); Teva (Inst)
Travel, Accommodations, Expenses - Lilly
 
Jeffrey G. Supko
No Relationships to Disclose
 
Andrew E. Place
Consulting or Advisory Role - Abbvie
Research Funding - Karyopharm Therapeutics
Travel, Accommodations, Expenses - Abbvie
 
Susan N. Chi
Travel, Accommodations, Expenses - Epizyme
 
Suzanne Shusterman
No Relationships to Disclose
 
Gina Hanna
No Relationships to Disclose
 
Jane O'Brien
No Relationships to Disclose
 
Suzanne Ezrre
Stock and Other Ownership Interests - Pfizer
 
Pei-Chi Kao
No Relationships to Disclose
 
Wendy B. London
No Relationships to Disclose
 
Steven G. DuBois
Honoraria - Loxo
Consulting or Advisory Role - Loxo
Research Funding - Curis (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Loxo; Roche/Genentech